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William A. Wood, Julia Whitley, Dominic Moore, Andrew Sharf, Robert Irons, Kamakshi Rao,
Jonathan Serody, Jay Coghill, Donald Gabriel, Thomas SheaThe optimal mobilization strategy prior to autologous stem cell transplantation for patients with multiple
myeloma remains unclear. Mobilization with cytokines alone appears to yield suboptimal results in older pa-
tients as well as patients who have received prior lenalidomide. To avoid the marked cytopenias and risks of
hemorrhagic cystitis associated with the administration of cyclophosphamide, we investigated the efficacy
and safety of chemomobilization with an intermediate dose etoposide (VP-16; 375 mg/m2 on days 11 and
12) and granulocyte-colony stimulating factor (G-CSF) (5 mg/kg twice daily from day 13 through the final
day of collection). We reviewed our institutional experience with 152 myeloma patients mobilized with
this regimen. The addition of VP-16 to G-CSF resulted in successful mobilization in 100% of patients, includ-
ing 143 (94%) who collected successfully in a single day. A total of 99% of patients, including those with prior
XRT and/or prior lenalidomide or thalidomide therapy, collected at least 5  106 cells/kg in 1 or 2 days of
apheresis, and the median total number of CD341 cells collected in the entire population was 12  106
cells/kg. Collection was predictable, with 61% of patients collecting on day 111, and the rest between
days 17 and 113. There were no variables, including age, prior imid exposure, radiation therapy, or total
amount of prior therapy that were associated with suboptimal mobilization. Adverse effects of the regimen
included supportive transfusions required in 31 (20%) patients, and fevers requiring hospitalization or intra-
venous antibiotics in 26 (17%) patients. VP-16 and G-CSF appears to be a safe and effective mobilization reg-
imen for patients with multiple myeloma undergoing autologous stem cell transplantation, producing
excellent stem cell yield with the majority of patients requiring 1 day of apheresis.
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transplantationINTRODUCTION
Despite the development of new and effective
agents, autologous stem cell transplantation (ASCT)
remains an important therapeutic component of the
management of patients with multiple myeloma
(MM), and the use of this procedure has continued to
increase nationally and internationally [1]. Stem cellLineberger Comprehensive Cancer Center, University of
Carolina at Chapel Hill, Chapel, North Carolina.
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6/j.bbmt.2010.06.021mobilization can be accomplished by using cytokine,
most commonly granulocyte-colony stimulating factor
(G-CSF), alone or in combination with chemotherapy
[2,3]. The efficacy of G-CSF alone in certain patient
groups is quite good, although there have been
several different patient populations identified as
difficult tomobilize [4]. “Failure rates” ofG-CSF alone
have been variably reported between 1% and 40%
[5,6]. In a recent, large phase 3 study, only 34% of
patients mobilized with G-CSF alone were able to
collect 6  106 CD341 cells/kg in 2 days of apheresis
[7]. Recent data demonstrates the adverse impact of
receipt of prior lenalidomide therapy on stem cell
mobilization, with the inability to collect .2  106
CD341 cells/kg in less than 4 days in 25% to 43% of
this patient populationwhenG-CSFalone is used [8,9].
In contrast, mobilization with chemotherapy in
addition to cytokine has been previously demon-
strated to increase stem cell yields at the time of col-
lection [10-12]. Most of this data has been reported141
142 Biol Blood Marrow Transplant 17:141-146, 2011W. A. Wood et al.with the use of cyclophosphamide (Cy) in addition to
G-CSF, in which stem cell yields and failure rates have
been improved in comparison to G-CSF alone. One
recent publication suggests that Cy can overcome the
effects of prior lenalidomide exposure [13], although
other data suggest that the use of Cy may impair stem
cell engraftment [14]. Other potential disadvantages
of adding chemotherapy to mobilization include in-
creased complications such as cytopenias requiring
transfusion support, febrile neutropenia requiring hos-
pitalization, and intravenous antibiotics, and unpre-
dictability regarding the optimal day for stem cell
collection [15,16].
Although there are data that support the ability of
high-dose etoposide (VP-16) to effectively mobilize
progenitor cells [17], there is little to no data available
regarding the routine addition of VP-16 to G-CSF in
the mobilization of patients with MM. We have cho-
sen to use an intermediate dose of etoposide (375
mg/m2 per day for 2 days) to preserve progenitor cell
mobilization and antitumor properties, while limiting
other potential toxicities including myelodysplasia,
mucositis, hepatic dysfunction, or prolonged cytope-
nias associated with higher doses of this or other
agents. We now report our institutional experience
with the safety and efficacy of this regimen.METHODS
Patients and Treatment
This analysis included patients between the ages of
27 and 72 who received mobilization with VP-16 and
G-CSF prior to ASCT for MM at our institution be-
tween 2004 and 2009. The mobilization regimen con-
sisted of placement of a central apheresis catheter
followed by outpatient administration of intravenous
VP-16 (375mg/m2) once daily on days11 and12. Pa-
tients received ondansetron 24 mg orally and dexa-
methasone 20 mg orally 30 minutes prior to each
VP-16 infusion, as well as prochlorperazine 10 mg ev-
ery 4 hours for nausea or emesis. Each VP-16 infusion
was diluted to a concentration of 0.4 mg/mL and in-
fused over 4 hours, followed by a 20-mL postinfusion
saline flush. G-CSFwas administered at a dose of 5 mg/
kg twice daily starting on days 13 and continuing
through the last day of stem cell collection. Antimcro-
bial prophylaxis was given concurrently using levoflox-
acin 500 mg orally once daily to all patients starting on
day 15. Peripheral blood CD341 cell counts were
checked routinely starting on day 111, except for cir-
cumstances in which patients were noted to have nor-
mal or high total white blood cell counts prior to day
111. Apheresis was initiated when the peripheral
blood CD341 cell count was $7/mL [18], and all pa-
tients had stem cells collected between days 17 and
113. Target volumes were calculated based on analgorithm that includes the patient’s weight in kilo-
grams, the peripheral precollection CD341 count,
and the requested cell dose (usually a minmum of
5  106 CD341 cells/kg and a target of 8  106
CD341 cells/kg). These were large volume aphereses
in approximately one-third of cases. All collections
were done using the COBE Spectra machine
(CaridianBCT, Lakewood, CO). Platelet transfusions
were administered routinely for platelet counts
#10,000, with higher thresholds used for patients at
a higher risk for clinically significant bleeding. ASCT
was performed using melphalan (200 mg/m2, reduced
to 140 mg/m2 for patients with renal dysfunction, age
over 65, or other comorbid illness), followed by stem
cell infusion the next day.Statistical Methods
The Kaplan-Meier (or product limit) method was
used to estimate the time to event functions of overall
survival (OS), time to relapse, and progression-free
survival (PFS). Fisher’s exact test was used for data cat-
egorized into 2  2 contingency tables. The nonpara-
metric Jonckheere-Terpstra method was used to test
for ordered differences among categories for larger
contingency tables. With this test, the null hypothesis
is that the distribution of the response does not differ
across ordered categories. For continuous covariates
of interest, the median values with its distribution
free 95% confidence intervals (CIs) were given.
“Poor mobilizers” were defined as those patients who
required .2 collections to obtain .5  106 CD341
cells/kg. “Poor engrafters” were defined as patients
who engrafted either neutrophils or platelets beyond
1 standard deviation from the median times to neutro-
phil or platelet engraftment for the entire cohort. Uni-
variable logistic regression was used to investigate for
a possible association between covariates of interest
and either “poor mobilization” or “poor engraftment.”
All analyses were performed using SAS statistical
software, version 9.2 (SAS Institute, Cary, NC). This
research was approved by the UNC institutional
review board.RESULTS
Patients
Between 2004 and 2009, a total of 152 patients
with MM underwent stem cell mobilization and col-
lection with VP-16 and G-CSF followed by ASCT
in 151 patients. Among these, 65 (43%) were male
and 87 (57%) were female. The median age at the
time of transplant was 56 years, with a range of 27 to
72 years. Patients had received a median 5 prior
months of antimyeloma treatment (range: 1.5-36
months), with 103 patients (68%) having received 1
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Figure 1. Percentage of patients collecting on days 7-13 from start of
mobilization.
Biol Blood Marrow Transplant 17:141-146, 2011 143Chemomobilization with Etoposideprior treatment regimen, 38 (25%) having received 2
regimens, and 9 (6%) having received 3 prior lines of
therapy. Eighty patients (53%) had previously received
thalidomide, and 29 patients (19%) had been treated
with lenalidomide, with a median lenalidomide treat-
ment duration of 6 (range: 1.5-12) months. Forty-
two patients (28%) had received prior radiation
therapy, including 4 patients who had been treated
with 2 separate episodes of radiation, and 1 patient
each who had been treated with 3 and 4 separate
episodes of radiation, respectively. Median bone mar-
row (BM) cellularity prior to mobilization for patients
with this information available on chart review was
40% (range: 5%-95%), with a median 5% plasma
cell involvement (range: 0%-30%) (Table 1).
Efficacy Characteristics
All patients (100%) collected successfully after 1
mobilization, with no patients requiring a second mo-
bilization or BM harvest. One hundred forty-three pa-
tients (94%) had stem cells successfully collected after
1 day of apheresis, and using our definition of “poor
mobilizers” (failure to collect 5  106 cells/kg in 1-2
days), only 2 patients (1%) were poor mobilizers.
Seven patients required 2 days of collection, 1 patient
required 3 days of collection, and 1 patient required
4 days of collection. Sixty-one percent of all patients
collected on day 111, with the remainder collecting
between days 17 and 113 (Figure 1). The median
peak peripheral blood CD341 cell count during the
collection period was 277.78 cells/mL and the median
CD341 cell number collected was 12  106 cells/kg
(range: 4.8 106-31.8 106), with all patients collect-
ing at least 4  106 CD341 cells/kg. One hundred
twenty-nine patients collected $8  106 CD341
cells/kg and 101 patients collected more than 10 
106 CD341 cells/kg. Following subsequent autolo-
gous stem cell transplantation in 151 of 152 patients
(with a median of 7.4  106 CD341 cells/kg trans-
planted), the median time to neutrophil engraftment
was 11 days, and the median time to a platelet count
.20,000 for more than 7 days without transfusionTable 1. Patient Characteristics
Variable Number
Total 152
Median Age (range) 56 (27-72)
Female sex (%) 87 (57%)
Total duration of prior therapy in months (range) 5 (1.5-36)
Number of prior treatment regimens (%):
1 103 (68%)
2 38 (25%)
3 9 (6%)
Previous treatment with thalidomide (%) 80 (53%)
Previous treatment with lenalidomide (%) 29 (19%)
Prior radiation therapy (%) 42 (28%)
Marrow cellularity percentage prior to mobilization
(range)
40% (5%-95%)
Marrow disease involvement at mobilization (range) 5% (0%-30%)was 16 days. There were a total of 10 patients who
were defined as “poor engrafters,” engrafting beyond
1 standard deviation, which was more than 14 days
for neutrophils and 27 days for platelets. Table 2 con-
tains measures of efficacy in the overall patient
population.
Because of the high efficacy of this mobilization
regimen and thus the very small number of “poor
mobilizers,” none of the following variables were asso-
ciated with poor mobilization in this patient popula-
tion: age, receipt of prior radiation therapy, duration
of prior chemotherapy, prior receipt and duration of
thalidomide, prior receipt and duration of lenalido-
mide, BM cellularity and disease involvement at the
time ofmobilization, and peripheral white blood count
and platelet count at the time of mobilization.
Although 2 of 29 patients (7%) with prior lenalido-
mide exposure (7 and 5 months duration of therapy, re-
spectively) were poor mobilizers, compared with 0 of
123patientswhodidnot receive lenalidomide, thenum-
bers are too small to draw anyfirmconclusions.None of
the variables that we analyzed for mobilization were as-
sociated with poor engraftment.Safety
Most patients underwent at least 1 interim blood
count assessment at our institution during the course
of mobilization, usually around day 18 (the rest hadTable 2. Mobilization Efficacy
Criteria Number
Successful collection after 1 mobilization 152 (100%)
“Good mobilizers” (>5  106 cells in 1-2 days) 150 (99%)
Patients collecting >10  106 CD34+ cells/kg 101 (66%)
Patients collecting >8  106 CD34+ cells/kg 129 (85%)
Days of collection required (%):
1 143 (94%)
2 7 (5%)
3 1
4 1
Median CD34+ cells/kg  106 collected (range): 12 (4.8-31.8)
Median CD34+ cells/kg  106 transplanted: 7.4
Median excess CD34+ cells/kg  106 saved: 4.7
Median days to neutrophil engraftment 11
Median days to platelet engraftment 16
144 Biol Blood Marrow Transplant 17:141-146, 2011W. A. Wood et al.blood counts checked elsewhere); among 133 patients
who were assessed, 105 were found to be neutropenic.
22 patients (14%) required inpatient hospitalization for
treatment of fevers during themobilization period, and
4 additional patients were administered outpatient in-
travenous antibiotics. Of the 26 patients requiring hos-
pitalization or outpatient antibiotics, 12 were found at
the time of these events to be neutropenic. Twenty-
four patients (16%) required transfusions with red
blood cells between the first day of etoposide infusion
and the last day of collection, and 9 patients (6%) re-
quired platelet transfusions. There were no cases of
treatment-related myelodysplastic syndrome (MDS)
or secondary acute myelogenous leukemia (AML)
identified in this cohort of patients after a median
time from transplantation for survivors of 28 months.Survival and Relapse Information
Of a total of 152 patients that had been followed
for survival information, 19 have died and 133 were
still alive at the time of analysis. Eighteen survivors
were alive 36 months or more after stem cell transplan-
tation. Themedian follow-up time for survivors was 28
months. One hundred seven patients remain alive and
disease free, and 45 patients have either relapsed or
died. Relapse free survival at 1 year was 76% (95%
CI: 67% to 83%) and OS at 1 year was 92% (95%
CI: 85% to 96%). A progression free survival curve is
shown in Figure 2.DISCUSSION
There remains little consensus about the optimal
method for mobilizing patients prior to ASCT for
MM, although increasingly there is recognition that
some populations of patients are difficult to mobilize
with a standard regimen of G-CSF alone. In a recent
large phase 3 trial, in which the addition of plerixaforFigure 2. Progression-free survival over time.(AMD3100) to G-CSF was compared with G-CSF
alone, the placebo group experienced a 66% failure
rate as defined by an inability to collect 6  106 cells/
kg in 2 days [7]. This appears higher than other pub-
lished data, although different rates are somewhat dif-
ficult to compare because of differences in the baseline
populations and differences in definitions of “mobili-
zation failure.” Nonetheless, as outlined in Table 3,
mobilization success rates, CD34 cell yields, and total
number of apheresis days required all appear to be in-
ferior when G-CSF alone is used without the addition
of other agents.
Efforts to determine factors associated with poor
mobilization in MM have focused largely on age,
amount, and type of prior chemotherapy or biologic
therapy, and amount of prior radiation therapy re-
ceived [19-21]. In the modern era of newer
antimyeloma therapies, fewer transplantation-eligible
patients are exposed to melphalan prior to mobiliza-
tion. However, there are concerns about the impact
of prior lenalidomide exposure on stem cell collection
[22]. For this reason, the International Myeloma
Working Group (IMWG) has recently released sug-
gested guidelines for stem cell collection in patients
who have received prior therapy with novel agents.
These include the use of early stem cell mobilization
after 3 to 4 cycles of initial therapy, or the addition
of other mobilization agents in higher risk groups,
such as patients who have received more than 4 cycles
of therapy or who are older than 65 years of age [6].
Several prior studies have suggested that adding
chemotherapy, most often Cy, to mobilization can im-
prove cell yields when compared with G-CSF alone.
One recent publication suggests that the addition of
cyclophosphamide to G-CSF can overcome the effects
of prior lenalidomide exposure. An alternative strategy
that has been proposed to increase cell yields has been
the addition of plerixafor (AMD3100) to G-CSF, an
approach that was recently demonstrated to improve
the chance of successful mobilization in comparison
with G-CSF alone [7] (see Table 3).
A third approach involves the addition of VP-16 at
either high (.1200 mg/m2) [17] or intermediate doses
to G-CSF as part of stem cell mobilization in patients
with MM, as has also been done in other diseases [23].
We found the intermediate-dose approach to be highly
successful in all patients, including patients over the
age of 65 years, those who received more than 4 cycles
of prior therapy with lenalidomide, and patients who
had previously received radiation. Cell yields were ap-
proximately double those published with the use of G-
CSF alone, and were comparable to published cell
yields in patients receiving Cy for mobilization (see
Table 3). One hundred one patients (66%) in our co-
hort collected .10  106 CD341 cells/kg, which
would typically be a sufficient target for a tandem
transplant. It is possible that with larger numbers of
Table 3. Recently Published Mobilization Efficacy Rates in Patients with Multiple Myeloma Compared with the Current Regimen
Patients (N) Mobilization Regimen CD34 Yield  106 Collection in #2 Days (%) Failed Collection (%)
1547 G-CSF (control arm) 7.3 (0.1-42.7) 35% (‡6  106) 44.1% (<6  106 in 4 days)
34614 G-CSF 9.9 (7.6-11.9) Not reported Not reported
38420 G-CSF 4.6 (4.2-5.0) 78% (‡2  106) 6.3% (<2  106 total)
37014 G-CSF + Cy 10.3 (7.2-14.6) Not reported Not reported
1911 G-CSF + Cy 14.2 (4.9-236) Not reported 0% (<4  106 total)
1487 G-CSF + Plerixafor 13.0 (0.7-104.6) 78% (‡6  106) 13.2% (<6  106 in 4 days)
152 G-CSF + VP-16 12.0 (4.8-31.8) 99% ($5  106) 0% (<5  106 total)
G-CSF indicates granulocyte-colony stimulating factor; Cy, cyclophosphamide.
Biol Blood Marrow Transplant 17:141-146, 2011 145Chemomobilization with Etoposidepatients we may have seen an effect of prior lenalido-
mide exposure on mobilization, as 2 of 29 patients
who had received prior lenalidomide were found to
be “poor mobilizers.” Nonetheless, all patients, in-
cluding the 2 “poor mobilizers,” were able to have
stem cells successfully collected after 1 mobilization
without the need to proceed to a second mobilization
or BM harvest.
The safety profile of intermediate dose VP-16 and
G-CSF appeared acceptable, as more than 80% of the
population did not require treatment for fevers or sup-
portive transfusions during the mobilization period.
There were no cases of secondary MDS or AML
found, and although the follow-up period was rela-
tively brief, with the first patient in the cohort mobi-
lized in 2004, we might have expected to see cases of
MDS or AML by this time given the usually short
latency period of these diseases following etoposide
exposure [24]. It is possible that our use of middose
rather than high-dose VP-16 may have protected
against the development of this outcome, but this is
also consistent with other data demonstrating low-
risk for tMDS or sAML following VP-16-based
mobilization [25]. One potential advantage of the che-
motherapy plus G-CSF approach is improved tumor
control, as others have observed an antitumor effect
in myeloma patients following the outpatient adminis-
tration of VP-16 with G-CSF [17]. Although our study
does not attempt to address this directly, the 92% OS
and 76%PFS at 1 year compare favorably with thema-
jority of published reports [26].
The timing of collection with VP-16 and G-CSF
also appeared to be very predictable, with most pa-
tients collecting on 1 day. Finally, there was no obvious
adverse consequence of exposure to VP-16 on neutro-
phil or platelet engraftment after subsequent autolo-
gous stem cell transplantation.
In summary, the addition of intermediate dose
VP-16 to G-CSF in the mobilization of patients with
MMappears to result in safe, tolerable, and highly effec-
tive stem cell collection. This regimen appears to over-
come the effects of prior lenalidomide exposure and
other high-risk features usually associated with poor
mobilization. Further research is needed to determine
whether etoposide, cyclophosphamide, or plerixafor is
more efficacious and cost-effective in high-risk patientswith myeloma who are predicted to be poor mobilizers.
Additional research is also needed to identify which spe-
cific subpopulations of patients may not need the addi-
tion of a second agent to G-CSF for successful
mobilization, to improve cost, convenience, and safety
considerations for both patients and transplant centers.ACKNOWLEDGMENTS
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